Allogene Therapeutics (ALLO) Stock: Buy, Sell, or Hold?
ALLO - Allogene Therapeutics, Inc. Common Stock
$1.50
-0.04 (-2.60%)
▼
5d:
-9.09%
30d:
-24.24%
90d:
-28.23%
WAIT
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 05, 2026
Get Alerted When ALLO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: ALLO shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: ALLO shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: ALLO is currently trading at $1.50, which is considered oversold relative to its 30-day fair value range of $1.62 to $1.98.
Technical Outlook: Technically, ALLO is in a downtrend. The price is currently testing key support at $1.50. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: ALLO scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $9.00 (+500.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ALLO is in a downtrend. The price is currently testing key support at $1.50. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: ALLO scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $9.00 (+500.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.62 -
$1.98
Company Quality Score
41/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 500.0% below Wall St target ($9.00)
- WARNING: Composite score 41/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.62 -
$1.98
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$1.50
Resistance Level
$1.74
Current Trend
Downtrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.30
Wall Street Target
$9.00
(+500.0%)
Revenue Growth (YoY)
-100.0%
Share & Embed Analysis
Last updated: October 02, 2026 6:20 PM ET
Data refreshes hourly during market hours. Next update: 7:20 PM
Data refreshes hourly during market hours. Next update: 7:20 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ALLO showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
Annie Yoshiyama
SELL
9586 shares
2026-04-21
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$433 | 56 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$88 | 54 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$199 | 49 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$110 | 63 BUY |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$86 | 46 HOLD |
